SGLT2 Inhibitors May Slow Aging by Clearing Senescent Cells
Diabetes drugs like empagliflozin show surprising anti-aging effects — mimicking caloric restriction and reducing senescent cell burden.
20 articles
Diabetes drugs like empagliflozin show surprising anti-aging effects — mimicking caloric restriction and reducing senescent cell burden.
New research reveals how a key cellular protein prevents ferroptosis, a type of cell death implicated in aging and age-related diseases.
Flavo-Proxylane topical treatment plus ultrasound reduced skin laxity by 44% in people using weight loss medications.
Natural polyketide from marine bacteria enhances cholesterol removal and improves fat metabolism in liver cells and mice.
New cryo-EM structures reveal how LYCHOS protein senses cholesterol levels to regulate mTORC1 signaling, offering drug targets for aging.
Inclisiran safely reduced LDL cholesterol by 28% in adolescents with familial hypercholesterolemia, offering hope for early intervention.
Daily anthocyanin supplementation helped over half of prediabetic participants return to normal glucose tolerance in just 12 weeks.
A new ESRRA-ATG5 axis links mitochondrial recycling to arginine metabolism, and a plant polyphenol activates it to protect diabetic kidneys.
A landmark RCT shows finerenone reduces eGFR decline and kidney-cardiovascular events in CKD patients without diabetes.
Novel obesity drug targeting two pathways simultaneously shows unprecedented weight loss results in recent clinical studies.
A steroid hormone activates receptor GPR56 to block ferroptosis, a form of iron-driven cell death linked to liver disease.
50 nm polystyrene nanoplastics accumulate in mouse testes, degrading sperm quality and triggering iron-dependent cell death through a newly identified mitochondrial pathway.
New research reveals how the cholesterol medication bempedoic acid directly activates PPARα, boosting fat metabolism beyond its known effects.
New research identifies choline kinase alpha as a key driver of diabetic retinopathy and microvascular dysfunction.
A systematic review of 8 studies finds tirzepatide significantly reduces hsCRP and IL-6 across all doses and populations.
A dual-action therapy combining a glucose-responsive hydrogel with stem cell exosomes dramatically speeds diabetic wound closure in mice.
Researchers found a dual-target approach that selectively destroys the most treatment-resistant form of acute myeloid leukemia.
A mouse study reveals how aging and poor diet synergistically disrupt liver thyroid hormone metabolism, accelerating fatty liver disease — and why resmetirom may help.
New research examines whether the cholesterol-lowering drug inclisiran could benefit pediatric patients with genetic high cholesterol.
New research reveals semaglutide's liver benefits work independently of weight loss through specialized liver blood vessel cells.